CGON

CG Oncology, Inc. - Common stock (CGON)

About CG Oncology, Inc. - Common stock (CGON)

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Dallas, TX.

Details

Daily high

$77.30

Daily low

$74.22

Price at open

$75.74

52 Week High

$80.97

52 Week Low

$35.64

Market cap

6.6B

Dividend yield

Volume

229,566

Avg. volume

757,054

P/E ratio

-27.69

CG Oncology, Inc. - Common stock News